AI Article Synopsis
- Reported outbreaks of invasive group A Streptococcus (iGAS) infections have increased among people who inject drugs (PWID) and those experiencing homelessness in the U.S., alongside rising overall iGAS rates.
- A study analyzed iGAS infections from 2010 to 2017, identifying about 13% of cases linked to IDU or homelessness, with these groups experiencing significantly higher infection rates.
- The research concluded that addressing issues like skin infections and breakdowns in these populations could help reduce the rising incidence of iGAS infections.
Article Abstract
Background: Reported outbreaks of invasive group A Streptococcus (iGAS) infections among people who inject drugs (PWID) and people experiencing homelessness (PEH) have increased, concurrent with rising US iGAS rates. We describe epidemiology among iGAS patients with these risk factors.
Methods: We analyzed iGAS infections from population-based Active Bacterial Core surveillance (ABCs) at 10 US sites from 2010 to 2017. Cases were defined as GAS isolated from a normally sterile site or from a wound in patients with necrotizing fasciitis or streptococcal toxic shock syndrome. GAS isolates were emm typed. We categorized iGAS patients into four categories: injection drug use (IDU) only, homelessness only, both, and neither. We calculated annual change in prevalence of these risk factors using log binomial regression models. We estimated national iGAS infection rates among PWID and PEH.
Results: We identified 12 386 iGAS cases; IDU, homelessness, or both were documented in ~13%. Skin infections and acute skin breakdown were common among iGAS patients with documented IDU or homelessness. Endocarditis was 10-fold more frequent among iGAS patients with documented IDU only versus those with neither risk factor. Average percentage yearly increase in prevalence of IDU and homelessness among iGAS patients was 17.5% and 20.0%, respectively. iGAS infection rates among people with documented IDU or homelessness were ~14-fold and 17- to 80-fold higher, respectively, than among people without those risks.
Conclusions: IDU and homelessness likely contribute to increases in US incidence of iGAS infections. Improving management of skin breakdown and early recognition of skin infection could prevent iGAS infections in these patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938854 | PMC |
| http://dx.doi.org/10.1093/cid/ciaa787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) study.
Int J Drug Policy
November 2024
Faculty of Medicine, School of Health Sciences, University of Iceland, Iceland; Department of Infectious Diseases, Landspitali University Hospital, Iceland; Department of Science, Landspitali University Hospital, Reykjavik, Iceland.
Background: Limited data exists about treatment outcomes in nationwide hepatitis C virus (HCV) elimination programs where injection drug use (IDU) is the main mode of transmission. In 2016 Iceland initiated the HCV elimination program known as Treatment as Prevention for Hepatitis C (TraP HepC). Factors associated with HCV cure in this population are examined.
View Article and Find Full Text PDFPrevalence of HCV Infection Among People Experiencing Homelessness in Madrid, Spain.
JAMA Netw Open
October 2024
Centro de Investigación Biomédica en Red en Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
Article Synopsis
- Hepatitis C virus (HCV) microelimination focuses on detecting and treating hidden infections in vulnerable populations, particularly people experiencing homelessness (PEH) who may suffer from substance use disorders, highlighting the role of point-of-care testing and peer support in infection prevention.
- A study conducted in Madrid from 2019 to 2023 assessed active HCV infection among PEH, utilizing rapid testing methods and analyzing various risk factors, including substance use and financial instability.
- Out of 2,709 screened PEH, 13.4% tested positive for HCV antibodies, with a prevalence of 6.3% for active infection; key risk factors identified were injection drug use (IDU) and associated behaviors, leading to
Factors associated with experiencing stigma, discrimination, and negative health care treatment among people who inject drugs.
Int J Drug Policy
June 2024
The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.
Introduction: Stigma has negative consequences for the health of people who inject drugs and people living with hepatitis C virus (HCV). This study evaluated factors associated with stigma related to injecting drug use (IDU) or HCV and those associated with being treated negatively by health workers.
Methods: ETHOS Engage is an observational cohort study of people who inject drugs attending drug treatment clinics and needle and syringe programs in Australia.
Birth cohort-specific consideration in an Emergency Department Hepatitis C Testing Programme: A description of age-related characteristics and outcomes.
J Viral Hepat
May 2024
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
The emergency department (ED) has increasingly become an important public health partner in non-targeted hepatitis C virus (HCV) testing and referral to care efforts. HCV has traditionally been an infection associated with the Baby Boomer generation; however, recent exacerbation of the opioid epidemic has resulted in a growing number of younger cohorts, namely Millennials, also impacted by HCV. Examination of this age-related demographic shift, including subsequent linkage success and linkage barriers, from the perspective of an ED-based testing and linkage programme may have implications for future population and health systems interventions.
View Article and Find Full Text PDFHigh prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment.
Harm Reduct J
January 2024
Department of Medicine, School of Medicine, University of California, San Francisco, CA, USA.
Background: Due to shared modes of transmission, coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is common, and HBV vaccination is recommended for all persons with HCV who remain susceptible to HBV. To identify potential gaps in HBV vaccination among this high-risk population, we aimed to determine the patterns of HBV susceptibility in persons undergoing community-based HCV treatment.
Methods: We performed a cross-sectional study within two community-based HCV treatment programs in an urban US setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!